Apollomics APLM
NASDAQ APLM
$23.86 -1.02 (-4.04%)
As of: Sep 10, 2026 · 11:04 AM EDT

Apollomics (APLM) Receivables - Net (2025)

Apollomics' (APLM) quarterly Receivables - Net came in at $2.3 million in Q4 2025, down 67.99% quarter-over-quarter from $7.2 million in Q2 2025.

Analysis

Apollomics (APLM) Receivables - Net (2025) Analysis & Trends

Apollomics (APLM) has reported Receivables - Net for 1 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.

  • On a quarterly basis, Receivables - Net changed N/A year-over-year to $2.3 million in Q4 2025; TTM through Dec 2025 was $2.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.3 million, changed N/A from the prior year.
  • Receivables - Net was $2.3 million for Q4 2025 at Apollomics, down from $7.2 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $7.2 million in Q2 2025 and troughed at $2.3 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Apollomics 34.50 Mn 31.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 2.31 Mn
Jun 30, 2025 7.20 Mn